Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115563 · ClinicalTrials.gov registry record · NA
Daily Amino Acid Supplementation for People With Parkinson's Disease
A NA study of Parkinson Disease (PD), sponsored by Cristina Colon-Semenza.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07115563: Recruiting NA study of Parkinson Disease (PD), sponsored by Cristina Colon-Semenza.
NCT07115563 is a NA study of Parkinson Disease (PD) that is actively recruiting participants, run by Cristina Colon-Semenza. The registered enrollment target is 30 participants, roughly in line with the 32-participant average among 3 other Parkinson Disease (PD) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07115563, a NA study of Parkinson Disease (PD), is actively recruiting participants, sponsored by Cristina Colon-Semenza.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid supplement increase essential amino acids (nutritional status)? Does the tailored amino acid supplement increase an antioxidant (complex amino acid) and decrease an amino acid associated with oxidative stress? Does the tailored amino acid supplement improve physical and mental health compared to a placebo supplement? Researchers will compare the tailored amino acid supplement to a placebo (a look-alike substance that contains no active ingredients) to see if the tailored amino acid supplements work to support health for people with Parkinson's disease. Participants will: Take the tailored amino acid supplement or a placebo every day for 6 months, visit the lab at baseline, after 3 months, and after 6 months for fasting blood draws, body composition assessment, and physical and mental health testing and keep a diary of their food intake and supplement intake.
Primary Outcome
Circulating amino acid concentrations will be measured from blood samples using high performance liquid chromatography using a solid phase column specifically designed to test amino acids (e.g. 00F-4435-E0, Phenomenex, USA) along with appropriate column guards (e.g. AJ0-7597 \& KJ0-4282, Phenomenex, USA) and liquid phases. This analysis will be performed at the Laboratory of Mass Spectroscopy and Omics Analysis.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Control (placebo)
- DIETARY_SUPPLEMENT Targeted Amino Acid Supplement
Study Locations (1)
Connecticut
- University of Connecticut - Storrs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2027-11 |
| Phase | NA |
What NCT07115563 shows while recruiting
NCT07115563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, roughly in line with the 32-participant average among 3 other Parkinson Disease (PD) trials with a reported enrollment target.
The record links to 1 condition, with Parkinson Disease (PD) appearing as the primary indexed condition, and to 2 interventions - of which Control (placebo) is the first listed.
NCT07115563 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT07115563 about?
NCT07115563 is a clinical study titled "Daily Amino Acid Supplementation for People With Parkinson's Disease". The goal of this clinical trial is to learn if a tailored amino acid supplement works to help adults living with Parkinson's disease to improve nutrition, metabolic function, body composition, and physical and mental function. The main questions it aims to answer are: Does the tailored amino acid s...
What is the current status of trial NCT07115563?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-10-31. Estimated completion is 2027-11.
What conditions does trial NCT07115563 study?
This clinical trial studies the following conditions: Parkinson Disease (PD).
What interventions are being tested in trial NCT07115563?
The interventions under investigation include: Control (placebo) (DIETARY_SUPPLEMENT), Targeted Amino Acid Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07115563?
This trial is sponsored by Cristina Colon-Semenza, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115563 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease (PD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI